Good morning and good afternoon, and welcome to the Novartis Q2 2021 results release conference call and live webcast. Please note that during the presentation, all participants will be in a listen-only mode and the conference is being recorded. After the presentation, there will be an opportunity to ask questions by pressing star and one at any time during the conference. A recording of the conference call, including the Q&A session, will be available on our website shortly after the call ends. Should anyone need assistance during the conference call, they may signal the operator by pressing star and zero. With that, I would like to hand over to Mr. Samir Shah, Global Head of Investor Relations. Please go ahead, sir. Thank you very much, good morning and good afternoon, everybody. Big thank you to all of you again for participating in this call and spending the time to listen to our quarterly results. The information presented today contains forward-looking statements that involve known and unknown risks, uncertainties, and other factors. These may cause the actual results to be materially different from any future results, performance, or achievements expressed or implied by such statements. For a description of some of these factors, please refer to the company's Form 20-F and its most recent quarterly results on Form 6-K that respectively were filed with and furnished to the U.S. Securities and Exchange Commission. Thank you again, and with that, I'll hand across to Vas Narasimhan. Thank you, Samir. Thanks, everyone, for joining today's conference call. Today with me, I have members of our executive team, and I also would like to introduce Karen Hale, our new Chief Legal Officer. Karen joins us from the biopharmaceutical industry with over 20 years experience in a broad range of medical devices and pharmaceuticals. Welcome, Karen. If we could move to slide five. I wanted to start by reflecting on the journey we've been on as a company, as we focused the company, rolled out our strategy, and delivered consistent performance over the recent period. Going back to the first half of 2018, when you look at our financial performance over the first halves of the subsequent four years, our sales have grown at 6% CAGR, our core operating income at a 13% CAGR, and we've grown our Innovative Medicines margin from 31.8% to 36.8% in the first half of 2021, demonstrating that our operational execution has been strong. When you look ahead, we remain confident in our growth outlook as we outlined in Meet the Management last year, where we highlighted a 4% CAGR off of our 2019 actuals to a 2025 sales goal of $60 billion or more, a consensus IM margin that is currently at 37.6% that we remain confident that we can achieve. A strong performance track record and a strong growth outlook remains the story for Novartis. Going to slide six. When you look at our strong performance in Q2, it was strong across all of the key elements that we believe will drive long-term value for our patients as well as for shareholders. Our sales growth was strong. Harry will go through that in a bit more detail. We had strong productivity with good core operating income growth and good margin expansion. We continued our innovation agenda, which will be critical to driving the growth to 2025, importantly, beyond. We also continued on our journey to be a leader in ESG with some important milestones. I'll talk about each of these areas in turn. Moving to the next slide. When you look at our key growth drivers and launches over the period, we demonstrated, I think, strong performance across our key brands. Marie-France will talk a bit more about the strong performance of ENTRESTO, COSENTYX, and ZOLGENSMA, as well as KESIMPTA, which is off to a good and strong start. Susanne will also cover the various oncology growth drivers. Taken together, our key growth drivers and launches now account for 51% of our IM sales. These products are growing at a rate of 29% in quarter two, which I think nicely demonstrates our transition from an older portfolio of medicines to a next wave of portfolios, which we believe will enable us to drive our growth over the next decade. Moving to slide eight. I also wanted to say a word on Sandoz. We saw the business stabilize in quarter two. We saw sales at 5% in the quarter. Biopharma sales were also up 5%, and core operating income was also up. When you look at the story for the rest of the year for Sandoz, we continue to expect disruptions related to COVID, but we do expect also, assuming healthcare systems continue on their current trend, a return, hopefully, back to a more stable situation. We have had a historically weak cough and cold season and decreased anti-infectives use. We will see how this fall unfolds, and again, we're hopeful that we can get back to a more stable situation overall in the generic sector. That said, we are confident in the longer-term outlook in Sandoz. We've made, we believe, the right investments in biosimilars. We've doubled the size of the biosimilars pipeline with a focus in key therapeutic areas such as oncology and immunology. We continue to also invest in our core generics capabilities. We strengthened our antibiotics manufacturing setup, as well as brought in new portfolio of assets, including our recent acquisition of GSK's anti-infectives portfolio. We continue to make investments in complex generics, including oncology injectables and respiratory medicines. Over time, we remain committed to delivering a Sandoz outlook of mid-single-digit sales and mid-to-high 20 core operating income margin. Moving to the next slide and turning to innovation. Q2 continued our progress on the innovation front. We had approvals of COSENTYX in the U.S. in pediatric psoriasis, as well as ENTRESTO in essential hypertension in China, which can be another growth driver for ENTRESTO, building on its already strong performance. I'll say a bit more on some of these other milestones in subsequent slides, but I did want to note that asciminib, our ABL001, has been filed in the U.S. in the third-line setting, and we do believe this medicine has blockbuster potential in the third-line setting alone, not to mention our efforts to move it into earlier lines, which I'll say more about. We also had important advances on KYMRIAH and alpelisib as well, which I think will enable us to broaden the indications for both of these medicines. Moving to slide 10 and taking a little bit of a deeper dive on our portfolio, starting with our life cycle management. I already mentioned the China approval in essential hypertension, but for COSENTYX, we remain on track for the hidradenitis suppurativa readouts in the second half. There is strong open label data that supports the use of COSENTYX in this indication. We also have a range of other indications we're developing, as we've noted, to enable COSENTYX to continue its strong trajectory. We're on track for KISQALI's MONALEESA-2 OS readout in the second half, which would be the third OS readout. Two have already been favorable for KISQALI, really building on the unique profile we believe KISQALI has. We also are on track for the adjuvant readout in 2022. We'll speak more about LEQVIO in a moment. Turning to pharmaceuticals, we'll go through iptacopan's data in a bit more detail, I wanted to highlight as well that ligelizumab's CSU studies are on track for phase III readouts in the second half. We have also initiated and are progressing chronic inducible urticaria studies as well as food allergy studies. We have continued to progress branaplam with an agreement now with the regulators for a start in the second half of a phase II-B study in Huntington's disease. Moving to oncology, our canakinumab readouts are also on track. For Lu-PSMA, we have submissions planned for the second half, and we've started the phase III studies in the earlier line settings. I'll say a bit more about that. I also wanted to highlight that with TNO155, our SHP2 inhibitor, we've already now advanced both in combination with other KRAS agents but are also now moving into the clinic with our SHP2 in combination with our own KRAS agent, JDQ, as well as other SHP2 combinations that we're currently exploring. Lastly, I wanted to note that asciminib now has entered our wild card box on the bottom here in first-line setting where asciminib is going against investigator choice of TKI. Our hope is if we were able to deliver this result, we would be able to once again transform the care of CML patients with a multi-blockbuster potential indication for asciminib. It's worth noting that across the wild cards you see in that box, while these programs are still early, each one of them has the potential to be a multi-billion dollar medicine if we're ultimately able to deliver on the clinical value of these assets. Moving to slide 11, saying a bit more on inclisiran. You likely saw that our PDUFA action date is now January 1, 2022. We have filed the brief files from our Schaftenau site, which is the manufacturing location where we currently do secondary manufacturing for products such as COSENTYX as well as other biologics. It's a site that's well known to the regulators. We also have, I believe we've addressed the concerns that FDA has raised, and it's notable that FDA has not raised any concerns related to the efficacy or safety of inclisiran in any of the interactions that we've had. This is a Class 2 resubmission, a six-month timeline. We of course, will continue to work with FDA to see if there's opportunities to move this up earlier in the time period, but hopefully now this will get us to a place where we can bring this very important medicine with a very substantial potential for the company to market in the United States. Moving to the next slide, turning to Lu-PSMA, you likely saw in the ASCO plenary session the medicine had really remarkable results of a 38% reduced risk of death and a 60% improvement in rPFS. Regulatory submissions are on track for the second half. The movement into earlier line studies with the PSMAfore and the PSMA ddition studies are already underway. We're also evaluating whether to move the medicine even into earlier line settings. We're working very hard to also expand the relevant capabilities to administer the medicine, and Susanne will speak more about that in a moment. Moving to the next slide. Iptacopan continues to show its utility across a broad range of indications, as you saw in the quarter. With IgA nephropathy, we presented the primary endpoint at ERA-EDTA, a 23% reduction in proteinuria at three months. It's important to note that this was a three-month time point. We expect that proteinuria over time to continue to improve as we typically see in studies like this. We look forward to looking at the six-month and beyond endpoints. Importantly, there was a stabilization of renal function, which will be very important from a regulatory as well as clinical utility standpoint. The APPLAUSE-IgAN nephropathy study is now ongoing to support the filings worldwide in this indication. We also continue to progress our C3G indication for this medicine with EU PRIME designation already achieved. We had a 49% reduction in proteinuria with this medicine at three months. Again, we would expect that trend to hopefully continue in subsequent months. A stabilization of renal function, also well-tolerated, and this phase III study now is enrolling to support filings worldwide. Moving to the next slide. When you look at iptacopan in PNH, we also presented data here in the frontline setting to complement the data we already have as an add-on therapy. This new data, which we presented at EHA, showed clinically important benefits of monotherapy iptacopan, this novel agent, with its ability to inhibit Factor B with both the impact intravascular and extravascular hemolysis, gives us hope that we can be ultimately indicated for frontline usage as well as add-on to eculizumab. Worth noting, it's unique as an oral agent with a great safety profile. We look forward to completing the APPLY-PNH studies with the superiority endpoints again to support filings worldwide. As you likely saw as well in our recent investor day on this medicine, we have a broad range of indications also now advancing. We believe this medicine has a substantial potential to treat a range of immunological, renal, and hematological diseases. Moving to the next slide. One piece of data that came out in the quarter that didn't attract as much attention as what one might have expected is our ZOLGENSMA SPR1NT data. This was remarkable data showing the impact that gene therapy can have on children with SMA. In this study, 100% of the patients met the primary endpoint of sitting independently when treated in the presymptomatic setting. These are patients who are identified through newborn screening and treated with ZOLGENSMA. 100% of patients met the secondary endpoint. With respect to walking and standing, we saw remarkable gains for these patients, which we hope will continue to improve over time. This data reinforces that ZOLGENSMA is a foundational therapy for presymptomatic and symptomatic children with SMA. It also continues to give us confidence that over time, as gene therapies as a sector matures, our capabilities in gene therapy, having learned so much with the introduction of ZOLGENSMA around the world, building outstanding manufacturing and technical capabilities, will allow us in the long term to be a leader in gene therapies for the decades to come. Moving to the next slide. I also wanted to say, as a last note on the pipeline, an update on the sabatolimab STIMULUS program, which is progressing in MDS and AML. As a reminder, in phase I studies, we showed that sabatolimab had 58% ORR in myelodysplastic syndromes. Given its unique mechanism of action, it's the first IOA agent in the hematological setting. It gave us confidence to move forward in MDS and AML with the STIMULUS programs, which are pivotal studies that tackle both of these indications. Now, the parallel execution of these trials offers us a range of filing options. We did have the CR readout, and the DMC recommended that we continue the study blinded to the PFS readout, and then, of course, the OS readout as well will come over time. It's also worth noting in the MDS program, we have a third study in the STIMULUS array of studies that also looks with a triplet combination including venetoclax. We believe we have a program that can adequately cover the range of potential options that would be needed for patients to be treated effectively with a medicine such as MBG. We remain very excited about the program. We think scientifically, mechanistically, and as a first-in-class asset, it can be an important addition to AML and MDS treatment, an area that we've been a leader in for many years. We'll look forward to keeping you updated on this program. Now moving to ESG. We had strong progress on ESG. I think some notable milestones in our effort to be a leader in this space. We reached 1 billion courses of antimalarial treatment delivered since 1999. It's 1 billion patients we've been able to treat with our Coartem pioneering agent to treat malaria. Very proud of that achievement. We also recently announced a 10-year commitment to empower 1,200 African American students working with historically black colleges and universities to really address the inequities in medical education and broadly inequities in healthcare in the U.S. You can see other important milestones that we hit over the course of the quarter. We'll look forward to continuing our progress on this front and being a leader in ESG for the long term, ultimately embedding this into our business to drive long-term performance. With that, I'll hand it over to Marie- France. Thank you, Vas. Good morning. Good afternoon to all. Pleased to update you on our Q2 pharma performance. If we move to slide 19, we delivered 12% growth versus prior year and an additional $1 billion in revenues. As you can also see, we also continue to make progress in our portfolio shift. Our growth drivers and launches are showing excellent momentum with 35% growth. These now contribute to more than 50% of our top line, thanks to our strong focus on execution. You can expect this shift to continue as we invest behind our growth drivers and launches and also actively manage the mature portfolio. If we move to slide 20, COSENTYX delivered 21% growth. U.S. volume growth in Q2 is now back in line with the market. Sales were up 11% quarter-over-quarter. Our field force activity is above pre-COVID levels. As we see the market regaining momentum, we also intend to capture more volume. Ex-US, we had really strong growth in Europe. In China, we quadrupled sales versus Q1 following the NRDL listing in March. Full year, we're on track to deliver double-digit growth based on our broad access, our ongoing geographic expansion, and the continued investment. We can now proudly say that 500,000 patients have been treated with COSENTYX. With our ambition to expand to 10 indications, we know that many more can benefit. We'll continue to invest with additional approvals in the short term and with our hidradenitis suppurativa readout towards the end of the year. If we move to the next slide, ENTRESTO saw another very strong quarter with 46% growth. In the U.S., you can see from the NBRx growth that we're really capitalizing on the ACC consensus recommendation and also on the expanded label. In Europe, the ESC guidelines now recommend ENTRESTO as first-line. That is further reinforcing our position as first choice. China, we tripled sales compared to previous year on the back of strategic account expansion. In fact, China is now ENTRESTO's second-biggest market. This team is strongly focused on execution, educating prescribers on guidelines, activating patients, and ensuring the guidelines become protocol at hospital level. You can expect to see the usual summer slowdown. However, full year, we will stay strong as we address the remaining 70% of patients who do not yet benefit from ENTRESTO. If I move to slide 22, ZOLGENSMA's continuing its growth trajectory as we open up reimbursement in new markets. As you heard Vas say earlier, we've got compelling data in presymptomatic patients, and thus it's really important for us to continue the work to implement newborn screening. As we know, the earlier we treat, the more transformational the outcomes are for these babies. In the U.S., 80% of newborns are being screened, and this is allowing treatment within a few weeks of birth. Ex-U.S., we expect to see Italy and the U.K. and additional reimbursed markets to drive the growth in the second half. Even though you can continue to expect some volatility in the quarterly pattern, we're on track to exceed blockbuster status this year. Our pre-clinical studies for IT are progressing well, and we're actually ready to start our phase III as soon as the FDA gives us the green light. Over time, the IT formulation could more than double the number of patients who could benefit from ZOLGENSMA. If we move to the next slide. With KESIMPTA, our focus is on broad adoption in early lines of therapy. We've added 500 new prescribers, and we've doubled the number of patients on KESIMPTA versus Q1. We also see that half of the KESIMPTA usage is in naive or first switch, and this is exactly where we want to be. The B-cell class is currently leading the recovery of the dynamic market, and KESIMPTA's got the second highest NBRx share in the MS space. This positions us well as the market opens up further. As we move to the second half of the year, we know what we need to do to double demand, and we're doing what is needed for a strong Q4. We're maintaining our leading share of voice to really increase the awareness of KESIMPTA. We also believe that our PIRA and our IgG data provide important clinical differentiation. We're fully focused on what we need to do. We're also fully focused on delivering a positive customer experience. In fact, 80% of patients are receiving their first dose within five days, and our patient support services are enabling fast and easy initiation. If I move on to slide 24 and move on to LEQVIO. We all know that ASCVD is the leading cause of death, and unfortunately, mortality is on the rise. There are effective treatments, we know that too, but patients are not at goal due to access, adherence, and affordability challenges. This is why we're taking a different approach on how we bring LEQVIO to market. In the U.S., we've got a new action date for January, and we're preparing for launch. Our access strategy could actually enable 2/3 of patients at launch to access LEQVIO with a $0 copay. We're working with healthcare systems on broad adoption. We're using our existing infrastructure to identify patients and also to set up buy and bill administration. In the U.K., we're partnering with the NHS to bring LEQVIO to more than 300,000 patients at risk of a second CV event over the next three years, and we're on track for that launch in Q3. We understand this approach will take time and further evidence generation, but this level of ambition is absolutely necessary if we want to drive better outcomes for ASCVD patients. In summary, an excellent quarter. We're fully focused on our strategy to maximize our growth drivers, deliver our launches, and also prepare for the next wave of innovative medicines. As we further accelerate our portfolio shift, we're also transforming our business. We want to be much more customer-centric and also pursue innovative approaches to launch our products in partnership with healthcare systems around the world. Coming out of Q2, we had good momentum across the globe, which we expect will continue in the second half. I want to take a moment to recognize the fantastic teams around the world for their hard work and for delivering these results. Over to you, Susanne. Thank you, Marie-France, and moving to slide 26, I'm very pleased to give an update on the oncology business. The oncology business showed very solid performance in the second quarter, delivering 7% of growth, with sales reaching $3.9 billion. Our growth drivers and recent launches are showing good momentum, with 19% growth versus prior year, driven by KISQALI, Jakavi, PROMACTA, Revolade, and KYMRIAH. Together, these products now contribute to half of the overall oncology sales, allowing us to more than offset losses from continued generic erosion of Gleevec, AFINITOR, and Exjade in the U.S. In Q2, the oncology market continued to be affected by COVID-19. Oncologists are reporting that their caseload, depending on geography, is still 25%-50% below pre-COVID level. Most affected areas are our breast cancer portfolio, recent launches, and hospital-initiated therapies like KYMRIAH and LUTATHERA. Looking at KYMRIAH, this grew globally 19%, it was driven by strong ex-U.S. growth and geographic expansion. In the U.S., we remain very competitive. However, overall demand in the class has slowed down. LUTATHERA sales were growing 10% in Q2. The ex-U.S. growth was double-digit, and we also saw positive signals in the U.S. as it is emerging from COVID-19 and referrals started to increase. Overall, we remain confident that patient visits to hospitals will increase and treatment patterns will further improve in the second half of the year, leading to acceleration of growth in these segments. Moving to slide 27, I wanted to share a bit on our performance in the U.S. U.S. remains our biggest market globally and is contributing to over 40% of our overall oncology sales. Our growth brands and launches contribute to 49% of sales. The U.S. market is slowly recovering from the pandemic, with oncologist caseload now reaching 75% of pre-COVID level. Testing rates for the most common tumor types remain suppressed in Q1, delaying diagnosis and new prescriptions. In Q2, we have seen partial recovery of our growth drivers and recent launches, together growing 10% versus the previous year and also accelerating versus the previous quarter. This was mainly driven by PROMACTA, KISQALI, and TAFMEK. With continued recovery of the market, we expect acceleration of sales in the U.S. in the second half of the year. Moving to KISQALI on slide 28. KISQALI delivered strong performance in the second quarter, growing 36% with sales of $225 million. The uptake was mainly driven by continued momentum and patient share gains ex-U.S. and particularly in Europe. KISQALI is the market leader in premenopausal setting in France, Italy, and Spain. In the U.S., we have also seen KISQALI sales getting traction, delivering 17% versus the previous quarter, driven by increased demand and new patient starts. We see increased field force reach in those accounts where access restrictions were lifted, and we also continue to leverage digital engagement based on dynamic targeting. At ASCO, we presented updated OS data from our MONALEESA-3 trial that showed consistent OS benefit with a median OS of 4.5 years. With this data, KISQALI demonstrated the longest OS in post-menopausal patients and is the only CDK4/6 inhibitor with data in first-line with fulvestrant. We believe that these excellent results may be attributed to the unique profile of KISQALI versus other CDK4/6 inhibitors with a preferential inhibition to CDK4 over CDK6 and a high concentration to inhibit the target. We are going into the adjuvant setting with our NATALEE study, exploring KISQALI in both intermediate and high-risk population. Just to remind you, this population represents around 70% of the adjuvant early breast cancer population, and there's a clear unmet medical need. I am very pleased to report that the enrollment of the NATALEE study is completed, and we are on track for readout in 2022. Moving to slide 29. As you heard from Vas, we are very excited about data from the VISION trial that positions lutetium PSMA well to potentially address the unmet needs of more than 80% of men with late-stage advanced prostate cancer who express PSMA receptors. Just to remind you that prostate cancer is the second most diagnosed cancer globally, and in the majority of cases, patients unfortunately develop metastasis by the time of castration-resistant prostate cancer diagnosis. Earlier in June, we got Breakthrough Therapy granted by the FDA. Filing to FDA is on track for the second half of 2021. We are fully in launch preparation with focus on the top 200 treatment centers and are also working on raising awareness on the clinical relevance of PSMA. Very pleased to see growth in the PSMA. Awareness has doubled among the target physicians over the last months. Just to reassure you that we have adequate capacity to meet the demand for the current launch. Our focus will be on driving referrals from community centers where 70% of prostate cancer patients are treated. When you model the lutetium PSMA launch, keep in mind that hospitals need to set up processes and licenses, and patients need to be selected through PSMA PET scannings. These factors are likely to drive a more gradual uptake at launch versus what you saw with the bolus effect on LUTATHERA. Moving to the next slide 30, I would like to talk about a launch preparation for asciminib, the first STAMP inhibitor that has the potential to transform CML treatment standards again. In the phase III ASCEMBL study, asciminib nearly doubled the major molecular response at 24 weeks compared to bosutinib. We have completed filings for FDA and EMA earlier in June, and the FDA has granted two Breakthrough Therapy designations and Fast Track designations for asciminib, and is reviewing the file under Real-Time Oncology Review. As we are preparing for the launch, our focus is on raising awareness on the importance of STAMP inhibition to overcome resistance and minimizing off-target events typical for TKIs. Aided awareness has already reached 75%, and just to remind you, the third-line indication for asciminib has already blockbuster potential. We are also very excited by the potential benefit that asciminib may provide to CML patients in first-line setting. Despite the advancements in treatment of CML over the last 20 years, there are still around 50% of patients who relapse or are intolerant to imatinib in first-line, and more than 30% of patients suffer from TKI-related non-hematological AIs. We believe that in earlier lines of CML treatment, asciminib may prevent resistance to currently available TKIs, and therefore, we are initiating a phase III study of asciminib versus investigator selected TKIs, with enrollment planned to start in the second half of 2021. Moving to slide 31. We have made great progress on our innovation agenda, and 2021 is a very important year in terms of readouts and submission. In addition to the VISION data, we had multiple readouts, like positive data from iptacopan in PNH, alpelisib in PROS, KYMRIAH in follicular lymphoma, and OS data for LUTATHERA. Canakinumab readout in second-line non-small cell lung cancer did unfortunately not show positive data, but it is very important to mention that we have two more studies ongoing in first-line and adjuvant non-small cell lung cancer, with the first-line trial on track to read out in second half of 2021. Later in the year, we're also expecting KYMRIAH to read out in second-line non-Hodgkin's lymphoma and KISQALI OS data from MONALEESA-2. In terms of submission, we have completed submissions for GvHD for Jakavi in Europe and Japan, TABRECTA in Europe, and asciminib in third-line U.S. and Europe. For H2, we are on track for filing of lutetium PSMA, KYMRIAH in follicular lymphoma and 2nd-line non-Hodgkin's lymphoma, and tislelizumab in non-small cell lung cancer and 2nd-line esophageal cancer. Exciting times ahead for oncology. Big thank you to all the teams. With that, I hand over to Harry. Yeah. Thank you, Susanne. Good morning and good afternoon, everybody. I'm now going to walk you through some of the financials for the second quarter and the first half of the year. As always, my comments refer to growth rates and constant currencies unless otherwise noted. On slide 33, you see the summary of our operating performance for the second quarter and the first half. We had a strong quarter two, resulting in a solid first half performance despite the impact of COVID-19 during the period. Quarter two net sales grew 9% to $13 billion, driven by our key growth drivers. Core operating income grew 13% to $4.3 billion, mainly driven by the higher sales and favorable gross margin, partly offset by higher investments. Core EPS growth was also up 16% to $1.66. Free cash flow grew 17% in US dollars to $4.2 billion. Of course, we appreciate the benefit on comparison from the low base in quarter two 2020 due to the COVID-19 destocking in the prior year. However, even when excluded, we still returned to healthy growth with sales up 5% on core operating income growing 4% quarter two 2021 underlying. Our half one performance was solid with 3% growth on the top line and 2% on the bottom line. Core EPS grew 5% to $3.17, and free cash flow was $6 billion. Of course, for half one to quarter two, quarter one destocking, stocking from the prior year has washed out. These values represent underlying growth of half one 2021. Next slide, please. On slide 34, I want to dive into our performance during the quarter by division. Innovative Medicines delivered a strong quarter with +10% top line and +14% bottom line growth and a margin of 37%. Even if we adjust for last year's lower base, we still saw strong growth with Innovative Medicines sales increasing 7% and core operating income up 6%. The Innovative Medicines performance was driven by continued strong double-digit growth of our key growth drivers, including COSENTYX, ENTRESTO, ZOLGENSMA, and the oncology launch brands. As Vas mentioned earlier in the presentation, our growth drivers and launches are driving portfolio rejuvenation and now account for over half of our Innovative Medicines sales. Of course, the pandemic still impacts our business, particularly Sandoz Retail and the anti-infective segment. The Sandoz business is now beginning to stabilize, with sales up +5% in quarter two and bottom line growing 3%, although growth did also benefit from prior year destocking. Turning to our full-year guidance on slide 35. We confirm full-year guidance for both the group sales and core operating income. For sales, we continue to expect low-to-mid single digit growth in 2021. For the bottom line, we expect mid-single digit growth ahead of sales. For Innovative Medicines and Sandoz, we are also not making any changes. We continue to expect Innovative Medicines division sales to grow mid-single digit and core operating income to grow mid-to-high single digit ahead of sales. For Sandoz, we continue to expect sales to decline in the low-to-mid single digit range and core operating income to decline low-to-mid teens. The key assumption for the guidance is that we see a continuation of the return to normal global healthcare systems and prescribing dynamics in the second half of this year. In addition, we continue to assume that no GILENYA and no Sandostatin LAR generics would enter in 2021 in the U.S. On the next slide, we provide some detail on our expectations for the second half of the year. We expect top line growth to accelerate from 3% in half one to mid-single digit, bringing us to the low-to-mid single digit range for the full year. Our assumption is that this will be driven by growth acceleration as we continue to return to normal prescribing behaviors, as well as further Sandoz stabilization. We expect core operating income growth to be high single digit in half two, reaching our mid-single digit expectation for the full year. Core operating income growth will be driven by higher sales and ongoing productivity programs, partly offset by increased investments in our growth drivers and pipeline. It is possible that we could reach the higher end of the ranges we have provided. As you know, the COVID situation still remains fluid. Finally, on slide 37. As currencies are constantly changing, I want to bring to your attention the estimated currency impact on our results using the current exchange rates. If mid-July rates prevail for the remainder of 2021, the full year impact of currencies on sales would be positive 2% and on core operating income, + 2% to +3% points. For quarter three, it would be + 1% point on sales and + 1% to +2% points on core operating income. As a reminder, we always update this estimated currency impact on our website on a monthly basis. With that, I hand back to Vas. Thank you, Harry. Moving to the next slide. When you look at 2021, we have a broad range of catalysts still to go. We've also had good pipeline delivery over the course of the year. We look forward to keeping you updated as we continue to advance these assets and programs. I'd also note our mid-stage pipeline continues to generate, I think, exciting new innovations, which we hope will emerge and be able to add to our pipeline over the course of the second half. Moving to the last slide, just to close. As I noted at the beginning, our consistent long-term performance over the recent years is driving our confidence for the future and the continued growth outlook for the company. We've had strong performance in Q2 driven by the key growth drivers, as you've seen throughout the presentation. We've also continued to advance our pipeline of novel medicines. You've seen the positive readouts across iptacopan, Lu-PSMA, and others. We're reconfirming our full year 2021 guidance, our commitment to drive long-term accretive growth. Again, thank you for your commitment to the company. With that, I'll ask the operator to open the line for questions. Thank you. As a reminder, to ask a question, you will need to press star one on your telephone. To withdraw your question, press the pound hash key. Operator, if I could just say one thing. If questioners could limit themselves to two questions, we'd appreciate it. Thank you. Thank you. Your first question today comes from the line of Wimal Kapadia from Bernstein. Please go ahead. Oh, great. Thank you very much for taking my questions. Wimal Kapadia from Bernstein. I'm just curious how Novartis are thinking about the potential impact of the SGLT2s for ENTRESTO following some of the recent positive data in the preserved ejection fraction population. These drugs have quite a robust profile in heart failure, are reasonably well priced, and have demonstrated efficacy on top and in ENTRESTO- naive patients. Do you expect to see any impact? I'm just curious on your level of confidence that these drugs will not be used ahead of ENTRESTO. My second question is just on iptacopan. Lots of interesting data recently for the drug across multiple indications. I'm just curious how Novartis is thinking about it from a commercial perspective. I appreciate this will come down to timelines and which indications demonstrate efficacy in phase III. They're quite a different size of markets, and competitive dynamics are quite different. Ultimately, how Novartis is going to prioritize should we see success across multiple indications, particularly given the acceptable price points by indications could be quite different, and competition from the likes of Apellis could limit the potential. Thank you. Yeah, thanks, Wimal. First on the SGLT2s, Marie-France? Thanks for the question. As you rightly said, the SGLT2s are add-ons, we expect them to continue to be used predominantly in diabetes patients. Even if we think about the new readout of path, we've really only seen the press release, and we'd have to look at the full data because the trials were really quite different. The bottom line is actually, ENTRESTO has a unique position, and it's got a broad label in the U.S. that's covering five out of six patients with chronic heart failure. We're very strong with the cardiologists, and we're going to focus on making sure that 70% of the HFrEF patients who are on previous standard of care switch to ENTRESTO. I think between the compelling data, the strong guideline support that we have, the commercial infrastructure, the excellent team that we have in place, we have what it takes to continue the momentum with ENTRESTO. If patients need an add-on, then an SGLT2 is the right thing to do. Thanks, Marie-France. With respect to iptacopan, I think our overall strategy, as you can see, is to fully leverage the unique mechanism and profile of this medicine across the range of indications we've outlined. Of course, it'll be data-driven, and the sequencing will be determined by the data. Our goal is, on the one hand, to disrupt existing markets with the fact that we have a safe oral that can be given broadly to patients who at the moment are taking IVs on an ongoing basis, we think there's a very attractive profile there. To enter into completely new market segments in renal disease, hematological illnesses that currently don't have a very strong standard of care. That's how you're going to see us approach the launch, fully maximize the asset across the full range of numerous indications we're pursuing. Thanks, Wimal. Next question. Thank you. Thank you. Your next question comes from the line of Graham Parry, Bank of America. Please go ahead. Great. Thanks for taking my question. First one's on COSENTYX. Just wondering what percentage of drug dispense was free drug in the first half and how you expect that to be in the second half. Because you said you expect demand to double 2 H, and I think if you take first half sales and add on twice that, you get to around consensus of $350. If you're getting less free drug, could you actually beat the consensus number? Secondly, on the NATALEE trial, now that recruitment's complete, can you narrow the window down to when in 2022 we might see the data? Even just as that, do you think it's a first half or a second-half event? Thank you. Thanks, Graham. On COSENTYX, Marie-France? On COSENTYX, our key focus is really on broad adoption in early lines of therapy. I say that because I think it's really important for our strategy that everyone understand that we want to ensure the value of high- efficacy B- cell therapy early. As I said in my opening comments, we have about 500 new prescribers. We've also got about twice as many patients on COSENTYX's Q1. All patients are starting on free drug, even though our free to paid conversion is happening really quickly, there's always a bit of a lag. In the second half of the year, we know what we have the fundamentals in place. We know we still have some scaling to do around familiarity of the brand, given that COSENTYX is new in market. We're going to continue our focus on leading share of voice on the differentiation and really on consistently enabling fast and easy initiation. For the full year, we're comfortable with external expectations. We know what we need to do to double demand in Q2 and really deliver a strong Q4. Medium term, we expect COSENTYX to be a major growth driver for the company. Thanks, Marie-France. On NATALEE timing, John? Yeah, thanks for the question, Graham. On NATALEE, which is our adjuvant study for KISQALI, as we disclosed earlier last year, that we've increased the recruitment from 4,000 to 5,000 patients. This includes both the intermediate and high-risk patients who have had advanced breast cancer. Our final result that we expect to read out is going to be at the end of next year, and that's how it's currently powered. As we said previously, we're not disclosing interims, so we're currently powered for the end of the year, next year for our final readout. Thanks, John. Thanks a lot for the questions, Graham. Next question, operator? Thank you. Your next question comes from Jo Walton from Credit Suisse. Please go ahead. Your line is open. Thank you. My first question is about marketing spend. We saw in the second quarter of last year, clearly, very little on the sales side and a dramatic constriction of everybody's marketing spend. Could you give some idea of how you've opened that up? What sort of level of your marketing capacity you're at now in the second quarter as you enter the third quarter? How you think marketing spend might be able to be sustained at perhaps a lower level going forwards, I don't know, more use of digital or whatever, but if we can get a sense of whether you feel or how confident you are in a reduction in your long-term marketing spend because of all the things that you've learned with COVID. My second question would be to ask for a bit more detail on China. You've talked about drugs where you've tripled sales, quadrupled sales. Can you just give us a little bit of an idea of your level of investment and your level of ambition in China, please? Yeah. Thanks, Jo. First on marketing spend trends, I'll hand it to Harry. Harry? Yeah. Hi, Jo. On the marketing spend, it's actually playing out as we guided to early in the year, which is, as you pointed out, quarter two spend is quite higher than last year quarter two, where basically all major markets were in lockdown, maybe other than China, but also the U.S. That's why we guided also that in the first half, we wouldn't see margin improvement. I think with the sales of 3% and core operating income of 2%, we saw that also playing out. I would expect continued, especially quarter three, where also last year spend levels were low, that marketing and sales growth is at a certain healthy level given the investment needs. That, of course, within our guidance, be it on our productivity programs, on manufacturing, and overall the expected sales growth, that then in the second half, also as we had more normal, I would say, spend levels in quarter four last year, that this plays out or laid out that in half two we will have some very nice margin improvement that leads to the full year guidance of margin improvement. In the midterm, I do expect that SG&A will be, together with manufacturing productivity on cost of goods, be the major driver of our margin increases, especially in Innovative Medicines to the high 30s. Certainly, a change in mix, somewhat a bit more to virtual, digital, but still face-to-face in most markets being important, especially for a launch initiation. I would expect that SG&A is one of the major drivers to continue to improve in the midterm our margin. Thanks, Harry. On China, Jo, first to take a step back. A few years ago, we began an investment effort in China, really putting in the necessary infrastructure, both in pharma and oncology, building out sales forces to really enable us to drive longer term growth. Second, we adopted a development strategy to bring our full portfolio of medicines to China, as well as including China in our phase III programs, at the start, so that given the changes in the regulatory framework there, that would enable us an earlier launch. Fast-forward today, we are growing in the high teens percentages in China overall from a business. We're on track on our stated goal to double the size of our China business from the 2020 baseline. We expect to be, if current trends prevail, one of the top three players amongst multinationals, if not more in China by 2024, 2025. That's driven primarily by new medicines, so overcoming any of the medicines that ultimately get tendered, our newer portfolio driving the growth. We have 50 potential approvals in that time frame, continued strong success on the NRDL listings, as you saw with COSENTYX. We expect China to become the second-largest market for Novartis in the world. We see profitable accretive growth being driven from there, and we'll continue to look to invest prudently in China over the years to come. Thanks, Jo, for the questions. Next question, operator. Thank you. Your next question comes from the line of Andrew Baum from Citi. Please go ahead. Your line is open. Thank you. A couple of questions, please. First on KISQALI and the NATALEE trial. Given the outcome of the PENELOPE-B trial with IBRANCE, how comfortable are you that your disease-free survival data that you'll have at the end of next year have sufficient duration on it to satisfy the FDA without wanting to see further follow-up? Then second question on business development. We've seen a rash of your competitors doing neurodegenerative deals. You've obviously had the surprising approval of aducanumab. How is that influencing your interest in the neurodegenerative space? Then if you could also comment on your chairman's recent comments of Novartis' interest in mRNA as a platform. Many thanks. Yeah. Thanks, Andrew. On the KISQALI situation, John, you want to take that? Sure. Thanks for the question, Andrew. As we've taken a look, as I said earlier, we've increased the number of patients in our NATALEE trial from 4,000, 5,000, including both intermediate and high-risk patients. As we look at this patient population, there's a couple things that we focus on. One is we have a longer treatment duration, looking at a duration of three years for the overall treatment. That should give us confidence in the approach. We've also looked at the adherence of patients, particularly in the first year. As we look at these patients, as you know, in the early treatment of these patients, micrometastatic disease is important. What we've seen, at least across both arms, is that the patients are adhering and staying on drug at the 400 mg dose. With those two specific components, we feel comfortable with the readout at the end of next year. Thanks, John. On business development, we of course are watching the changes in the approach to use of the accelerated approval pathway. As we've already noted, in neurodegenerative diseases, we have the ongoing program in Huntington's disease entering phase II-B, and we'll certainly consider how best to potentially bring that forward if there's a way to accelerate a regulatory submission, assuming positive clinical trials. Also internally, we've had neurodegeneration efforts within the country for many decades, as you know, and we continue to have programs targeting Alzheimer's disease, Huntington's, as well as other neurodegenerative diseases, both using biologics, RNA interference, siRNAs, and ASOs, as well as gene therapies. That will continue. No specific comments on BD&L in the neurodegenerative space. Of course, we are looking, as always, for attractive assets to bring in, given our broad-based efforts in neuroscience. On mRNA, again, not much more to add. I think we've watched how mRNA continues to have value in the COVID space and are curious to see could mRNA have applicability more broadly within the vaccine space. We have our own ongoing efforts internally, obviously with inclisiran in manufacturing for siRNAs, with pelacarsen, with antisense oligonucleotides. We're a substantial manufacturer of those technologies, and also have internal efforts on RNA interference. That work will continue, and we'll continue to evaluate if there is any sensible approaches in mRNA more broadly, but nothing imminent at the moment. Thanks, Andrew, for the questions. Next, question operator. Thank you. Your next question comes from the line of Mark Purcell from Morgan Stanley. Please go ahead. Your line is open. Yeah, thank you very much. First on KESIMPTA, I wonder if you could give us the NBRx share in the U.S. currently, then in terms of thinking about those 13 launches anticipated by the end of 2021, how we should think about the advantages and disadvantages of a subcut formulation for a B-cell therapy in those launch markets outside the U.S. Secondly, on inclisiran, two parts. First part, what are your latest thoughts around FDA site inspection? How should we think about the future supply split between yourselves and a third party? You sort of mentioned these new initiatives, V-INITIATE and V-INCEPTION, which are kicking off now ahead of outcomes data in 2026. Could you elaborate a little bit more on those initiatives and others you're looking to increase the evidence base behind inclisiran before we wait for those outcomes data? Thank you. Thanks, Mark. First on KESIMPTA subcutaneous outside the U.S., Marie-France? Yeah. KESIMPTA is an important launch for us outside of the U.S. If I look at Europe alone, we've got 420,000 patients living with MS, and many of these patients are on low-efficacy therapies. Actually, many more patients are on low-efficacy therapies versus the U.S. We're currently working through reimbursement and to accelerate access. What we also know is that a lot of these patients don't have access to infusion centers. Our research tells us that physicians and patients will appreciate a self-administered, high-efficacy therapy that can be used in the comfort of a patient's home. Right now, we're working with each country through their own reimbursement system, and we know what we need to do to bring KESIMPTA as quickly as possible to patients around the globe. On your NBRx question, currently, our NBRx share in the U.S. is 11%. I would also note on KESIMPTA, if you look at one case study in the U.K., our ability to get rapid access there, I think, demonstrates the value in ex-US markets of a subcutaneous formulation where the overall cost effectiveness of a therapy is high on the system's mind. On inclisiran, just on the manufacturing side of things, in the US, our intention at the moment is to focus production out of Novartis-owned Schaftenau facility. We can't predict on whether or not the FDA will inspect it. Notable that this site is regularly inspected, this very line has been recently inspected by FDA using a remote inspection and approved for use in a given indication. So, we'll have to see what the FDA ultimately determines, but I think it's notable that this is a line that's regularly used and inspected by the FDA. In terms of the data initiatives, maybe Marie-France on the efforts to build out data on inclisiran. Yeah. You saw some of that on the slide, and obviously, learning from ENTRESTO, we know that we need to build evidence generation. You know about our efforts on the outcomes data, so ORION-4. We're also looking at primary prevention studies. We're also looking to complement with the V-INITIATE trial, for example, on the different ways of accessing inclisiran when it comes to acute coronary syndrome or use or no use of ezetimibe. That's the level of evidence and generation that we want to build around the product so that we can ensure fast uptake. Thank you. I just want to add that we continue to work with various important parties. We hope to have updates over the second half of the year on our partnership with the NHS on inclisiran. That's something we've highlighted in the past. That'll be a very important proof point that inclisiran can be used at a large scale in healthcare systems. We're also partnering with major organizations in the U.S., such as the American Heart Association, and we hope to announce others, which I think will also demonstrate that we can generate evidence, but also generate large-scale utilization volume demand for medicine. We'll keep you updated as those happen. Next question, operator. Thank you. Your next question comes from the line of Emmanuel Papadakis from Deutsche Bank. Please go ahead. Your line is open. Well, thanks for taking the question. Emmanuel from Deutsche Bank. Maybe a question on sabatolimab, the MDS1 effective deferral for a PFS readout. I think the original fairly long-standing guidance has been for a filing on the CR readout in the second half of this year. What can we interpret on efficacy from that data monitoring decision or recommendation to continue until the PFS readout? Unless I'm mistaken, that's a couple of years away. Does that impact your guidance around that being potential blockbuster $1 billion+ indication? A question on ZOLGENSMA. You've given helpful guidance around 20% newborn screening rates in Europe. Does that inflect next year, or is it going to be a relatively slow incremental build? How are you progressing in terms of national-level discussions about, particularly in light of, as you said, presymptomatic data? If I may, just a quick one on the intrathecal. It sounds like not much has changed since Q1. I think you said then you had agreement on the trial design. You were waiting for the clinical hold to be lifted. Are those discussions ongoing, or has anything new actually happened in the last few months? Thank you. Yeah. Thanks, Emmanuel. First on the sabatolimab CR readout. John? Yeah, for the sabatolimab, as you know, this is our TIM-3 compound, our first-in-class IO therapy for myelodysplastic syndrome and AML. As we designed the study, we always had two primary endpoints, the first primary endpoint being complete remission and the second endpoint being progression-free survival. As we read out the complete remission, we reached the number of endpoints in the earlier part of this year. At that point, the DMC, Data Monitoring Committee, came back and told us to continue the study as originally planned. You've seen the slide that was shared earlier by Vas in terms of the number of readouts. As you've seen, we actually look at not only MDS, but also AML. As we look at this, we do think that this is a differentiated asset for not only for us to think about high-risk MDS, but also AML, based on the fact that it has a good safety profile and potentially, pending results, the efficacy in terms of durability of response. We await the results in 2022 and 2023. I think, Emmanuel, as we highlighted, there's multiple different filing options depending on how the results play out. It doesn't change our belief that the medicine, given it's a first-in-class asset that has a different mechanism than any existing therapy or a late-stage therapy, that it can be a significant $1 billion+ medicine. On ZOLGENSMA, on the incremental NBS and how we're doing on newborn screening, Marie-France, do you want to say a word about that? I would just say that, you know that in the U.S. that the newborn screening is high. Outside the U.S., it really is a market-by-market, it's gradual. I can give you some information. Germany will be implemented from October. We'll see parts of Belgium screening from the beginning of this year. We know that Poland is implementing gradually. We've got other countries across Europe that are doing this. It's a mixed picture. We're very committed to it. We know that it's really important to start ZOLGENSMA early. We saw that from the SPR1NT data and how amazing the results are when babies are treated early. It is a priority for us. Of course, medium-term, our goal is to bring ZOLGENSMA to older children once we get the IT formulation. Yeah, just another word on that. Thanks, Marie-France. On the intrathecal, there's no updates, Emmanuel. We continue to work through resolving the FDA's concerns. We do have the protocol finalized agreement with the FDA on the phase III design. We're preparing operationally for the study's execution with a belief that that indication can continue to be a multibillion-dollar indication for the company. As soon as we have any updates on the preclinical topic and resolution with the FDA, we'll of course provide it. Thank you. Next slide. Next question, operator. Thank you. Your next question comes from the line of Richard Parkes from Exane BNP. Please go ahead. Hi. Thanks very much for taking my questions. Just two questions. Firstly, on sales and margins, both your expectations for 2Q that you set out with the 1Q results. I just wondered if you could discuss what surprised you positively and confidence that those trends will continue, given that you haven't updated guidance. I just wondered if you could add your thoughts on impact of the Delta variant and maybe whether you've adjusted your planning assumptions for healthcare systems opening up on the basis of that. Secondly, just a question on some of your legacy oncology assets in the U.S., specifically PROMACTA, TASIGNA, and TAFINLAR. If I look at sales per script over the last few quarters, at least in the first half, it looks like sales per script's been growing in double digits, which seems to imply quite significant price increases. I just wondered whether you could discuss that trend and whether there are any other factors such as channel mix that might be impacting that. Thank you. Thanks, Richard. First on sales and margins outlook, Harry? Yeah. The line was a bit hard to understand. Richard, could you briefly repeat? Yeah. Harry, I think the question was, were there any things that surprised us versus the guidance we gave after Q1 on how Q2 would play out, and how do we potentially see the Delta variant impacting our guidance for the rest of the year? Yeah. Okay. Thank you. Richard, obviously, we delivered a bit more than what we thought. We saw in the U.S. a bit faster reopening, I would say, in most of our brands. Sandoz pretty much in line with expectation, but on Innovative Medicines, some better momentum overall. Also very good work from our manufacturing colleagues on productivity, in addition to always perfect supply levels. Overall, I would say slightly ahead of our internal expectations in quarter two. Yeah. Thanks, Richard. I think on the Delta variant, we continue to monitor the situation. What we are expecting is that given that healthcare systems have seen the impact when they had a shutdown to patients with non-communicable diseases and the substantial impact that had, we remain optimistic that healthcare systems will ensure that patients get the care they need while dealing with any surges that may or may not happen with respect to COVID-19. Now on PROMACTA, TAFMEK U.S. performance, Susanne? Yeah, thanks a lot. Richard, on PROMACTA, actually, we are very, very pleased with the performance. As you rightly note, 18% growth, it's really across all geographies. It is volume driven. It's really still our main indications, ITP and SAA. To give you a little bit more granularity, on the U.S., we had 11% growth. Maybe just to remind you, there was a label update earlier this year that makes PROMACTA even more competitive. We are seeing share gains increasing NRx. Of course, it is the efficacy driving that. It's also the oral convenience and it's the non-immunosuppressive benefit over competitors. Therefore, very strong performance. Ex-U.S., we saw 26% growth versus previous year. It's very strong underlying performance in major markets like the EU. Also just to mention, very strong performance in China, where we got an NRDL listing end of last year. Very pleased with PROMACTA. Similar on MEKINIST, TAFINLAR. We could really stabilize market share and are very competitive versus new entries. Very pleased with the growth also across geographies. Also to mention for China, we are very pleased we got TAFMEK included into the NRDL list. Really strong growth on volume base across geographies. Thanks, Susanne. Thanks, Richard. Next question, operator. Thank you. Your next question comes from the line of Seamus Fernandez from Guggenheim. Please go ahead. Your line is open. Great. Thanks for the question. Just two quick ones. As we think about the opportunity in MDS and for the TIM-3 asset, I was just hoping you could give us a little bit more color on the evolution. I just wanted to follow up on the previous question. Specifically as it relates to the CR response there, is that your conclusion there that the proceeding to the PFS benefit is a clear positive moving into the subsequent events, or is this just a continuation of the trial, which could be viewed as somewhat disappointing on that side of it for the high-risk MDS patient population? The second question. You guys are talking quite strongly about the opportunity for asciminib just in the third-line setting, blockbuster potential. Can you just talk about that relative? Is that predominantly relative to the bosutinib as sort of the primary opportunity and kind of replacing that asset or replacing that product sales, or is it really speaking to a broader opportunity in the third-line setting because of potential for duration of use expanding upon how that product's used so far? Thanks. Yeah, Seamus. Just in the interest of time, on the MDS, I think with the CR read out, I would say it's neutral to positive. Neutral is saying because we're blinded, we don't know what the DMC saw. I think the fact that the study will continue now to the next set of endpoints and the positive mechanism that we see in the previous data that we've seen on the product, we remain optimistic that both in MDS and AML, we can get to positive results and bring meaningful innovation to patients. As John noted, the studies have a range of different designs, including a third study that also takes into account venetoclax, a doublet and a triplet design. I think we have the bases covered, we look forward to getting the additional readouts over the coming year and a half. On the sales potential of asciminib, Susanne, do you want to say a word about this? Yeah, happy to take that, Vas. Maybe just on the opportunity on sabatolimab, just why we are very excited is because it's a completely novel mechanism. It's a TIM-3, so it has the potential to be the first immuno-oncology therapy in hematology, in MDS and AML. Why we believe that is important is because obviously there now has been made progress on having more efficacious treatments, but what we all know, durability and also safety profile is still remaining challenging. Therefore, we are very excited that sabatolimab would have this attribute to add really huge value to this medical need. On asciminib, to maybe lead you a little bit through, just to remind you a little bit on the dynamics in CML. There is still 10%-15% of patients that progress to third- line. What you also have to note, there is a significant number of patients that remain in second-line just because of lack of options for these patients. Moving to third- line, what we still see is a 75% failure rate, which of course is devastating. That's why there is still a big percentage of patients sitting in second-line, even if treatment is not optimal. Therefore, you see that is the pool we are targeting. We also, with asciminib, expect longer duration of the current treatment. That is where potential comes from. I think we still underestimate the earlier lines' potential. Of course, we have changed completely the outcome of CML. As I said, in first-line, usually patients are started on imatinib, and there is 50% of patients that relapse. What you also have to note that 30% of first-line patients are having issues with adverse events and really are struggling for such a long-term treatment. That's where, with the profile of asciminib, we expect to also add value there, and that's why we're also entering into first-line. Great. Thanks, Susanne. Next question. Thanks, Seamus. Next question, operator. Thank you. Your next question comes from the line of Kerry Holford from Berenberg. Please go ahead. Your line is open. Thank you. Yes, a couple from me, please. Harry, just on the second half outlook, you've obviously raised the pharma operating profit growth guidance slightly today, but you've not updated the growth guidance for the group. Although you've not changed the outlook for Sandoz in the second half, what is it within this division that prompts continued caution for that second half outlook, despite those improvements you've seen in Q2? Then on inclisiran. I think a question was asked on this earlier, but just to clarify, what are your plans for the manufacturing of that drug in the future? Can you remind us where the ex-U.S. supply is manufactured? Should we understand that the global manufacturing site is now the Austrian site, or should we anticipate further significant investment at some point, perhaps in the U.S.? Thank you. Yeah, thanks, Kerry. First on the Sandoz outlook on the second half, Harry. Yeah. Thank you, Kerry. We have to remember how quarter one and quarter two have developed here. Clearly you saw a very steep decline of quarter one, and then you saw that 5% growth of Sandoz in the second quarter. Underlying, if you take the prior year, it is talking out -1. We saw, as expected, a stabilization, but we have a first half with a 5% decline. In order to be at the low- to mid-single-digit decline in the full year, we continue to expect stabilization around broadly in line for the second half for Sandoz. I think that is, at this moment, a very reasonable assumption. Of course, we can all make scenarios around cough and cold and flu season in quarter four and the market dynamics for that. We have taken a midpoint scenario on this. Overall, I would say, of course, volatility, given the COVID situation and how the cough and cold season would be. Overall, I would say our guidance is quite, starting from a -5% decline in half one, quite reasonable that Sandoz would stabilize. They have a few first file launches in the second half, so that helps. We have to see also how the pricing in the U.S. continues to develop. I would say not overly cautious, but realistic. Thanks, Harry. Kerry, on manufacturing, it's important to note when you take a step back, our overall goal is to have Novartis be the primary manufacturer of both the upstream and downstream parts of this siRNA for inclisiran. We've made the necessary investments to do that. We have substantial manufacturing capacity to synthesize the siRNA. As we've noted, in the U.S., we'll move to using our Schaftenau facility. Over time, globally, the primary manufacturing will be done out of Novartis facilities being supplemented by CMOs as needed. The primary reason to do this is one, we believe the medicine will be, as we've noted, one of our most significant medicines. Second, from a cost standpoint, our goal is to drive significantly down the cost of goods to enable large-scale use of the medicine in the secondary prevention study and eventually perhaps in the primary prevention study. Right now, ex U.S., we do use third parties for both the primary and the secondary. Over time, the evolution will be the Novartis-owned facilities, and those investments have already been either started or completed. Thanks, Kerry. Next question, operator. Thank you. Your next question comes from Peter Welford from Jefferies. Please go ahead. Your line is open. Hi. Thanks for taking my questions. Just two, please. Firstly, on oncology, just looking at some of the hospital-administered drugs in particular, and also some of those that require either biomarker diagnostics, companion diagnostics to use, it actually looks as though the second quarter for some of those drugs was sort of relatively weak compared to the first quarter, or there certainly wasn't sort of an uptick. I'm thinking the likes of KYMRIAH and LUTATHERA, for instance. Also as well, I think things like even TABRECTA and other drugs. I wonder if you could just comment on what you're seeing there with regards to why, I guess, we're not seeing Q-on-Q improvements in oncology and how we should think about that perhaps in the second half of the year and the gating factors. Secondly, I just want to come back to Harry's comment that we could reach the higher end of the outlook ranges, but COVID situation remains fluid. Should we take that to mean that if COVID situation pans out as we currently see, the higher end of the ranges is where we should be thinking? Should we take that as thinking that you just don't know, and you still see uncertainties? I guess, curious where you're thinking with regards to the current COVID situation and whether the situation has to deteriorate significantly for that to be not valid. Thank you. Thanks, Peter. Just briefly, Susanne, on the hospital-administered oncology. Yeah. Thank you, Vas, and thank you, Peter, for the question. As I mentioned in my presentation, these areas that you mentioned, hospital-initiated areas, but also, of course, where you have new launches. This is still impacted by COVID, especially when you look at the U.S., that only 75% of patients are back versus pre-COVID levels. We still lack a fourth or 1/4 of patients volume that we usually saw. That is impacting, for example, diagnostics. It's impacting screening. That's, of course, TABRECTA would be such a brand where you see lower biopsies, you see lower testing rates overall. I have to say, when you look within the ones that are tested, TABRECTA and testing for c-Met is increasing, but it's just suppressed patient volumes. This is same what we see for hospital-initiated product. Just to give you some figures on KYMRIAH, as I said, 19% versus previous year. We saw that especially in the U.S., the whole class saw a reduced demand. While we stay very competitive with KYMRIAH, that is really linked to recent also manufacturing success rate that the customers are very pleased about. It's really the demand that we saw in the whole class going down. On LUTATHERA, there is some early positive signs in the U.S. We have seen growth versus previous year as some now referrals are started, but it's still very suppressed. We remain confident that with now the market opening up, centers taking more patients in, this should improve and accelerate. Yeah. Thanks, Susanne. Then Peter, on the outlook, as Harry noted, there are multiple dynamics, of course, we are monitoring. If the business dynamics continue as we currently see them, if oncology can continue its recovery, if Sandoz remains in a stable situation, given the strong growth we are seeing in our growth drivers, there is certainly the potential for us to be at the higher end of the guidance, and we will of course, keep you updated in quarter three. Next question, operator. Thank you. Your next question comes from the line of Laura Sutcliffe from UBS. Please go ahead. Your line is open. Hello. Thanks. First question is on LEQVIO, please. Have you dosed any patients in the U.K. under your program there yet? I think you said the program was starting this quarter. What setting will those early doses be given in? Are these patients being seen in the hospital, or have you managed to get it into primary care from the word go? Second question is just on ENTRESTO. Could you maybe talk a little bit about the uptake in the HFpEF population? Thanks. Yeah. Thanks, Laura. First on LEQVIO, the agreement, we're still working through the final stages with the NHS, so we have not yet dosed patients in the U.K. The agreement, though, has the aspiration that this would be rolled out in primary care from day one at scale, trying to address the ASCVD population and get the U.K. towards its long-term goal in cardiovascular health. We hopefully will have updates in the coming months on that pioneering initiative, which we hope will catalyze I think LEQVIO's global impact over the coming years. On ENTRESTO HFpEF, I'll just start taking the questions given the time. ENTRESTO HFpEF, we do see, I think, the uptake already, you can see that in the NBRx, it's still early days, I think as we continue the rollout and the education as well as the awareness on the guidelines, we would expect to see continued growth for ENTRESTO. We see a strong outlook for the brand. We're confident we'll be in that $4 billion-$5 billion range, as we continue to see the trajectory, we'll provide further updates on the long-term outlook for ENTRESTO in the coming months. Thanks, Laura. Next question, operator. Thank you. Your next question comes from Tim Anderson from Wolfe Research. Please go ahead. Your line is open. Thank you. On COSENTYX, thinking about bimekizumab, they've gotten some good exposure recently with publication of their data in "The New England Journal," beats your product on efficacy, has one side effect of oral candidiasis. How much do you think this product will impact COSENTYX and do you think that one side effect is a material impairment to their product in your view? On tislelizumab, your partnered PD-1, how realistically will you compete in a setting like lung in Western markets? Can you and your partner assure us you won't be disruptive on price? I ask because U.S. Merck guides for price erosion over time in the category. I'm wondering who's going to be driving that. Yeah. Thanks, Tim. First on COSENTYX, when you look at the dynamics, we've been able to take on competition consistently over the recent years, continue to grow the brand double digits, as Marie-France noted, 20%+. That's driven both in dermatology and in rheumatology. We note the additional competitors coming in. I can't comment specifically on bimekizumab, but we do think that COSENTYX's very clean safety profile, the fact that it's used in such a broad range of dermatology offices and consistently across patient types, its ability to address scalp, palmoplantar psoriasis as well as the joint manifestations and the fact that we have additional indications, we're not concerned by additional IL-17 entrants. Really our focus now, given that we've been able to effectively hold price in the U.S. market despite some disruptive attempts, we are confident now that our focus has to be on the next wave of indications to drive this brand well beyond the $5 billion benchmark we've already put out there. On tislelizumab, you've seen the esophageal cancer filing. We're moving towards first and second-line non-small cell lung cancer. We're able to market this medicine from a competitive standpoint, given our long presence, particularly outside the U.S., but also in the U.S. We'll be prudent in how we think about the pricing, we do think we can make a compelling value proposition longer term. The real opportunity for us is in combination. We'll be taking forward tislelizumab in combination with our SHP2 inhibitor, in combination with some of our RLT agents, amongst other opportunities. We're going to work to both maximize on the combination side, as well as take as much as we can of a very large PD-1 market, given the broad range of indications we expect the agent to have. Thanks, Tim. Next question, operator. Thank you. Your next question comes from the line of Simon Baker from Redburn. Please go ahead. Your line is open. Thanks for taking my questions. Two please, if I may, just going back to LEQVIO, I wonder if you could give us some idea of the ramp to 300,000 patients, given the unusual situation you have here, having not only agreed reimbursement, but also utilization. Secondly, moving on to Sandoz, how you gave the principal drivers for expansion of the IM margin over time. I wonder if you could do the same for the Sandoz margin. Thanks so much. Thanks, Simon. For LEQVIO in the U.K., it's going to be driven by our ability to work with the U.K. to get primary care physicians to diagnose these patients out of the NHS data systems and then rapidly get them onto LEQVIO. I think it'll be a slow initial ramp, and then we hope to see a rapid ramp up. In the U.S., we've done a very good job of targeting the relevant integrated health systems to hopefully be prepared to have a reasonable uptake initially, again, it will take time to get those centers on board. In parallel, we'll also have a traditional launch with our traditional sales and marketing approach, leveraging the ENTRESTO field force and reach. On approval in the U.S., we'll go, obviously, out very strongly. It will take time to get the brand up. Then once we think we get momentum, we expect the brand, as we've guided to be a very significant multi-billion dollar medicine for the company. Midterm Sandoz margins will be driven by a portfolio shift with the biosimilars portfolio, large number of biosimilars in the mid-20s we expect to get forward, get into the market and some of them first, hopefully, to market, such as natalizumab, amongst others. Then on top of that, the ability to launch additional injectables and oral solids while continuing to drive down cost of goods. You'll have a mix shift to higher margin products, as well as the continued efficiency gains and cost of goods. Lastly, Richard and team are working hard to optimize the manufacturing and sales set of leveraging digital technologies, and I think that will be the other element that will help us get to those mid-to-high 20s margins in Sandoz. Thanks, Simon. Next question, operator. Thank you. Your next question comes from Steve Scala from Cowen. Please go ahead. Your line is open. Thank you. I have two questions. First, on AVXS-101, can any findings from the preclinical intrathecal safety studies be shared with us today? That's the first question. On the second question, relates to the KISQALI adjuvant interim look in NATALEE. I'm curious if this look has already occurred. If it has, then it would seem to be a material update, and you would have announced it. I assume that it has not yet occurred, but please confirm. Thank you. Yeah, thanks, Steve. On AVXS-101, I see the preclinical data we've seen to date does not indicate any concerns. However, we need to complete the relevant assessments and, of course, ultimately agree with FDA on the lifting of clinical hold. So we'll keep you updated as that progresses. The NATALEE interim has not occurred, but as we've guided to, we're no longer guiding to interim analysis timings, and we're focusing on the final outcomes. John, as you mentioned earlier in the call, we expect that to be in the back half of next year. Of course, as we learn more in that study, we'll keep you updated. Thanks, Steve. Next question, operator. Thank you. Your next question comes from the line of Naresh Chouhan from Intron Health. Please go ahead. Your line is open. Hi there. Thanks for taking my question. Just two, please. In the U.K., we've recently seen increased instruction from hospitals, partly because of COVID and partly because of a very obviously eroded economy to work through. We've seen electives and oncology appointments being delayed as a result. Are you seeing early signs or anything similar in the U.S. as yet? Obviously, there's a few states where hospitalizations are rising pretty quickly. I was just wondering whether or not you're seeing early signs of that in the U.S. Secondly, on asciminib, do you expect [audio distortion] to be flagged on the label given what you saw in the earlier studies, and how do you expect that to add up, especially with generic suppliers [audio distortion]? Thank you. Yeah, thanks, Naresh. On the U.S., we currently don't see any shifts in utilization that are notable other than what we already stated in the call. Oncology is below pre-COVID levels. Cardiovascular is also below pre-COVID levels, so ENTRESTO continues to have very strong performance, and patients with heart failure seem to be getting the medicine as expected. Nothing that we can flag at this point, and also, no clinical trials are enrolling on time. We have learned a lot about managing, I think the healthcare systems have learned a lot about managing COVID. We've learned a lot about managing our trials and the uptake of our medicines during COVID. Hopefully we can navigate this next period successfully, but certainly something we're watching very closely. I think it's too soon to comment on specifics on asciminib's label. I would note that the safety profile was remarkably clean when you look at the It was a head-to-head study versus dasatinib across all relevant safety markers. It was a very clean profile. Patients stayed on drug. We're optimistic that overall, the asciminib profile will be attractive, which is a part of the reason as well, as Susanne mentioned, we're quite confident that if it ultimately proves superior, it can be a very effective first-line therapy. Next question, operator. Thanks, Naresh. Thank you. Your next question comes from Martial Descoutures from ODDO BHF. Please go ahead. Your line is open. Good afternoon. Thank you for taking my question. I would like to come back on the Sandoz business, and thank you for your previous answer on the H2. We understand the next step with the top-line improvement driven by the pipeline with biosimilars and the selection of complete generics. Could you share with us your vision on the improvement of the profitability in the midterm? Do you see any concrete operational leverage on the cost due to the improvement of the top-line expected and the affiliated cost plus the price erosion? Should we consider stabilization of this activity for the next year? If you could give us more color maybe to help us to manage the COVID margin in the next quarter and beyond. Thank you very much. Yes. Martial, I don't think I fully picked up the question, but I'll give my best answer. When we look at Sandoz's evolution over time from a margin standpoint, first, right now, our goal is to invest and create a very strong pipeline performance in this period of time, both biosimilars and oral solids. In the coming years, you're not going to see big shifts in the margin or the operating leverage. Our belief is given Richard is driving very strong efficiency gains across all the relevant P&L items, and we continue to expect important pipeline delivery in biosimilars, in respiratory, in oral solids. When that pipeline delivery happens, then we expect the margin in the midterm to be accretive and move up into that mid-to-high 20s. The shape is going to be stable for the period next few years, and then we expect acceleration and margin improvement for Sandoz as that portfolio ultimately comes through. I think that's the best way to think about it. We have one more question. Operator, could we go to the last question? Thank you. Thank you. Your last question today comes from Keyur Parekh from Goldman Sachs. Please go ahead. Your line is open. Thank you, thank you for taking my questions. Vas, if I may, your introductory comments on Sandoz, talking about the strategic vision in the long term seemed almost like setting the narrative for a 2022 decision on the longer-term outlook for Sandoz. Am I overinterpreting your comments, or is that the timeframe in which we should expect a broad decision on whether Sandoz is a part of Novartis or not longer term? That's question number one. Question number two, we are getting very close to on an annualized basis, the peak sales numbers you provided for COSENTYX and ENTRESTO. I'm wondering why we haven't seen updated peak sales estimates for those two products. Is there anything from a competitive or a market perspective that worries you? Was this just not the right opportunity for you to address the longer-term peak opportunity for those products? Thank you. Thanks, Keyur. Good to hear from you. On Sandoz, there's no updates or changes. I mean, our goal right now is to put Sandoz in a strong position, invest in the business so that it can be on a track to be the leading generics company in the world, which we think it can be from a financial as well as impact standpoint. If and when we take any decisions or start a process, we'll of course let you know. Right now our focus is on the operational performance of Sandoz and supporting Richard and his team to driving that mid-single-digit growth and margin expansion that we've outlined. I think on your second question, I think we are very pleased with the trajectory of ENTRESTO and COSENTYX. You are correct that we are approaching the sales outlook of $4 billion-$5 billion we guided to in ENTRESTO and $5 billion+ in COSENTYX. Our current plan is that Meet the Management will provide an updated outlook on both of those brands, especially as we understand better the dynamics. Certainly would want to highlight we are confident in both of those brands to be very strong pillars of Novartis in the years to come. Thanks everyone for joining today's conference call. Apologies we ran a bit over. We'll keep you updated. Thank you for the interest in the company, and please stay safe and healthy, and we'll look forward to speaking soon. Thank you. Thank you. This concludes today's conference call. Thank you for participating. You may now disconnect.